Promoter Pandey Reclaims Control with Debt Financing

Narendra Pandey, founder of Asian Institute of Medical Sciences (AIMS), is set to regain full control of the hospital chain. 360 ONE Asset is providing about ₹600 crore in debt financing for Pandey to buy back the 49% stake held by private equity investors British International Investment (BII) and OrbiMed. The deal values Blue Sapphire Healthcare, AIMS's parent company, at roughly ₹1,200 crore. This move strengthens promoter ownership but significantly increases AIMS's debt load, raising questions about its ability to manage payments amid market shifts.

Deal Details: Valuation, Investor Exits, and Funding Source

The ₹1,200 crore valuation for AIMS's 450-bed Faridabad hospital works out to about ₹26.7 lakh per bed. While India's healthcare sector sees strong deal activity, with valuations often 25-30 times earnings for hospitals and listed firms trading at mid-teens to over 30x EBITDA multiples, AIMS's specific profitability metrics to support the debt aren't detailed. BII and OrbiMed had previously sought to exit their stakes but reportedly faced difficulties due to high valuation expectations. Other private equity firms, like KKR and General Atlantic, had earlier shown interest in a larger hospital chain at a ₹1,500 crore valuation, suggesting market appetite can vary. The ₹600 crore loan comes from 360 ONE Asset, which recently closed its fifth private credit fund with ₹3,500 crore commitments, aligning with its strategy of providing structured credit to Indian companies.

Risks of High Debt and Valuation Concerns

Using substantial debt for this buyback carries inherent risks. AIMS, despite reporting ₹490 crore in revenue for FY25, now must service a ₹600 crore loan. Healthcare companies typically see EBITDA margins around 23-25%. This means a large part of AIMS's operating profits could go toward debt repayment, potentially limiting funds for growth or leaving it vulnerable to rising interest rates. The fact that BII and OrbiMed's prior sale attempts stalled over valuation differences questions whether the current ₹1,200 crore valuation is sustainable, especially with a leveraged structure. While founder Narendra Pandey is a respected surgeon, his background is in medicine, not managing a heavily indebted company. Structured credit can hide financial strain if revenue or profit targets are missed.

Broader Trend and Future Challenges

This deal reflects a wider trend where Indian promoters use private credit to reclaim ownership in fast-growing sectors like healthcare. The Indian healthcare market continues to attract significant investment, with deal values over ₹10,000 crore in Q2 FY26 and projected growth of 11-12% annually. As AIMS increases its ownership, its ability to manage debt payments and sustain growth will be key. The success of this leveraged ownership strategy hinges on AIMS's operational performance and broader economic conditions, which could affect its future financing options or any potential IPO plans.